Aldeyra Therapeutics, Inc.
ALDXStock
$1.72−61.48%52W
Market Cap$115.82M
P/E—
Div yield—
Beta1.19
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-61.14%
Price vs S&P 500 (4W)10.06%
VGM Score33.26
Market Capitalization$115.82M
Earnings Surprise History
Q1 26-0.06est. -0.10
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALDXAldeyra Therapeutics, Inc. | — | — | D | $1.72 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Aldeyra Therapeutics is a clinical-stage biotechnology company developing medicines for immune-mediated and metabolic diseases. Its lead candidate, Reproxalap, is in late-stage development for dry eye disease and allergic conjunctivitis. The company's pipeline also includes candidates targeting retinal diseases, autoimmune conditions, and cancer.